Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients

Int J Clin Pharmacol Ther. 2013 Jan;51(1):67-9. doi: 10.5414/cpp51067.
No abstract available

MeSH terms

  • Antimetabolites, Antineoplastic / blood
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Apoptosis
  • Biomarkers, Tumor / blood*
  • Capecitabine
  • Cell Survival / drug effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Enzyme-Linked Immunosorbent Assay
  • Fluorouracil / analogs & derivatives
  • Fluorouracil / therapeutic use
  • Gemcitabine
  • Glycation End Products, Advanced / blood*
  • HMGB1 Protein / blood*
  • Humans
  • Pancreatic Neoplasms / blood*
  • Pancreatic Neoplasms / drug therapy*
  • Prospective Studies
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Glycation End Products, Advanced
  • HMGB1 Protein
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil
  • Gemcitabine